Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of bladder cancer

Abstract

Bladder cancer is one of the most common urothelial tumors worldwide. While there are some progresses on early bladder cancer detection, patients’ mortalities have not been changed significantly. So it is important to get further understanding the mechanism involved in the development and progression of bladder cancer. Long non-coding RNAs play important regulatory roles in a variety of biological processes ranging from gene regulation, cellular differentiation to tumorigenesis. Previous literatures reported that lncRNA ABHD11 Antisense RNA 1 (ABHD11-AS1) (Organism: Homo sapiens) was highly expressed in gastric cancer. Inspired by these observations, we hypothesized that ABHD11-AS1 possibly plays an analogous role in human bladder cancer. We first found that ABHD11-AS1 was up-regulated in bladder cancer tissues and cell lines, and ABHD11-AS1 expression level was positively associated with clinicobiological features. Cell proliferation, cell migration and apoptosis were observed by silencing ABHD11-AS1 and overexpression ABHD11-AS1 caused contrary effects. Taken together, these data suggested that ABHD11-AS1 may be an oncogene and a therapeutic target in bladder cancer.

LncRNA ABHD11‐AS1 promotes the development of endometrial carcinoma by targeting cyclin D1

“…Moreover, a tumorigenesis assay demonstrated overexpression of ABHD11‐AS1 promoted endometrial cancer cell tumorigenicity and tumour growth in vivo in nude mice. These observations are consistent with the reported roles of ABHD11‐AS1 in gastric cancer, ovarian cancer and bladder …”

“…LncRNAs represent a new frontier in molecular biology and play significant roles in epigenetic, transcriptional and post–transcriptional regulation of gene expression, are involved in normal cell physiology and participate in the development of various diseases, including cancer . The lncRNA ABHD11‐AS1 has been found to be overexpressed in gastric cancer, ovarian cancer and bladder cancer tissues . However, the role of ABHD11‐AS1 in endometrial cancer has not been reported.…”

A Panel of Urinary Long Non-coding RNAs Differentiate Bladder Cancer from Urocystitis

“…Recently, several reports have highlighted the role of long non-coding RNAs (lncRNAs) as urine-based biomarkers for diagnosis of bladder cancer [1,[10][11][12][13][14][15][16][17][18][19][20][21][22]. Long non-coding RNAs are transcripts longer than 200 nucleotides that are not translated into protein [23].…”

“…LncRNAs do not contain open reading frames, but have conservative secondary structures. LncRNAs could interact with DNA, RNA or proteins as molecular sponges, scaffolds and activators to play important regulatory roles in a variety of biological processes [11]. For example, Wang and collaborators [13] determined that high expression of UCA1 (Urothelial cancer associated 1) in urine sediments allows detection of high-grade superficial bladder tumors.…”

“…Encouraged by these successes, in this study, we attempted to discover and evaluate the prediction power of a panel of lncRNAs biomarkers to discriminate bladder cancer from urocystitis. We chose totally sixteen lncRNAs as our candidate biomarkers, as suggested by previous studies [1,[10][11][12][13][14][15][16][17][18][19][20][21][22]. We conducted a study of 140 NMIBC patients and 140 urocystitis patients.…”